Trial Profile
An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 28 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 28 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2022 Planned End Date changed from 1 Sep 2024 to 1 Jun 2025.